BOCA
RATON, Fla. and RICHLAND,
Wash., March 14, 2023 /PRNewswire/ -- PharmaLogic
Holdings Corp. ("PharmaLogic" or "the Company"), a contract
development and manufacturing organization and radiopharmaceutical
manufacturer, today announces the signature of a Master Services
Agreement with Viewpoint Molecular Targeting, Inc., a wholly-owned
subsidiary of Perspective Therapeutics, Inc. ("Perspective") (NYSE
AMERICAN: CATX), for the development and production of theranostic
candidates VMT-01 and VMT-α-NET. The radiopharmaceuticals are
currently in development for the diagnosis and treatment of
metastatic melanoma and neuroendocrine tumors (NETs),
respectively.
Under the terms of the agreement, PharmaLogic will produce and
supply doses of VMT-01 and VMT-α-NET for use in Perspective's
early-stage clinical trials. This will complement the existing
radiopharmaceutical GMP capability that Perspective already has at
its mid-west site.
Scott Holbrook, PharmaLogic's
Chief Strategy Officer and General Manager, stated, "Targeted alpha
therapy (TAT) with Pb-212 labeled radioligands offers one of the
most exciting platforms for novel cancer therapy within the rapidly
expanding precision radiotherapy ecosystem. The expertise of
Perspective Therapeutics and PharmaLogic are well aligned to yield
a successful collaboration around VMT-01 and VMT-α-NET."
"We are delighted to select PharmaLogic as a trusted CDMO
partner at this important juncture of the Viewpoint's clinical
development journey," said Thijs
Spoor, Perspective Therapeutics' CEO. "Radiopharmaceutical
diagnostic imaging and therapeutic agents have a limited shelf life
from time of manufacture to patient administration in the clinical
setting. PharmaLogic's domain expertise in radiopharmaceuticals and
broad national distribution footprint helps address our need for
specialty radiopharmaceutical manufacturing at the highest level.
As we have been given the safe to proceed authorizations from the
U.S. Food and Drug Administration, we look forward to commencing
enrollment of the Company's two image guided alpha-particle therapy
studies at multiple clinical trial centers around the country.
Furthermore, we look forward to reporting preliminary results from
the clinical trials later in the year."
"PharmaLogic is excited to partner with Perspective Therapeutics
on the production and distribution of these personalized
alpha-particle theranostics," said Chris
Parr, PharmaLogic's Vice President of Radiochemistry and
Technical Operations. "We value Perspective's scientific leadership
in this area and believe it aligns perfectly with our mission of
delivering clinically relevant precision medicine products to
patients in the communities we serve."
About PharmaLogic Holdings Corp.
PharmaLogic is a
world-class contract development and manufacturing organization
specializing in novel diagnostic imaging and therapeutic
radiopharmaceuticals for the treatment of cancers and other
malignancies. In addition to an established and reliable network of
radiopharmacies, PharmaLogic has decades of expertise in drug
development from discovery, through manufacturing and
commercialization. The Company seeks to take the lead in the
advancement of radiopharmaceutical technology for the benefit of
patients worldwide. For more information, visit:
www.radiopharmacy.com/
About Perspective Therapeutics
Perspective
Therapeutics, Inc., formerly known as Isoray, Inc., is a medical
technology and radiopharmaceutical company that is pioneering
advanced treatment applications for cancers throughout the body.
Perspective Therapeutics is the sole producer of Cesium-131
brachytherapy seeds and has a proprietary technology that utilizes
the isotope lead-212 to deliver powerful alpha radiation
specifically to cancer cells via specialized targeting peptides.
Perspective Therapeutics is also developing complementary imaging
diagnostics that incorporate the same targeting peptides which
provide the opportunity to personalize treatment and optimize
patient outcomes. This "theranostic" approach enables the ability
to see the specific tumor and then treat it to potentially improve
efficacy and minimize toxicity associated with many other types of
cancer treatments.
Perspective Therapeutics' melanoma (VMT01) and neuroendocrine
tumor (VMT-α-NET) programs are entering Phase 1/2a imaging and
therapy trials for the treatment of metastatic melanoma and
neuroendocrine tumors at several leading academic institutions. The
Company has also developed a proprietary lead-212 generator to
secure isotope supply for clinical trial and commercial
operations.
For more information, please visit their website at
www.perspectivetherapeutics.com.
Safe Harbor Statement
Statements in this news release
about Perspective Therapeutics, Inc.'s ("Perspective") and its
wholly-owned subsidiary Viewpoint Molecular Targeting, Inc.'s
("Viewpoint," and together with Perspective, the "Company") future
expectations, including: the functionality and capabilities of the
Company's therapies including its targeted alpha-particle
radiotherapy and its theranostic candidates VMT-01 and VMT- α-NET;
the potential size of the commercial market for the Company's
treatment programs; the Company's expectations, beliefs,
intentions, and strategies regarding the future; and all other
statements in this news release, other than historical facts, are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 ("PSLRA"). This statement
is included for the express purpose of availing the Company of the
protections of the safe harbor provisions of the PSLRA. It is
important to note that actual results and ultimate corporate
actions could differ materially from those in such forward-looking
statements based on such factors as whether the alpha-particle
therapy studies referred to in this news release are conducted on
the anticipated timelines or are successful; the ability to raise
ongoing capital to fund added costs of research and development
related to the Company's business; the ability of the Company to
manage growth and successfully integrate its businesses; whether
the Company can maintain its key employees; the risk that the
recent merger disrupts current plans and operations; the outcome of
any legal proceedings that may be instituted against the Company
following consummation of the merger; whether the Company's
anticipated product pipeline is achieved; whether additional
studies are released that reinforce the results of the studies
discussed in this presentation; whether the anticipated benefits of
the Company's therapies are realized; training and use of the
Company's products; market acceptance and recognition of the
Company's products; the Company's ability to enforce its
intellectual property rights; whether ongoing patient results are
favorable and in line with the conclusions of clinical studies and
initial patient results; successful completion of future research
and development activities; whether we, our distributors, and our
customers will successfully obtain and maintain all required
regulatory approvals and licenses to market, sell, and use our
products in their various forms; the procedures and regulatory
requirements mandated by the FDA for animal trials, human trials,
clinical studies, Phase I and II approvals, fast track approvals,
and 510(k) approval and reimbursement codes; changes in applicable
laws and regulations; and other risks detailed from time to time in
the Company's reports filed with the SEC.
Unless required to do so by law, we undertake no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise. For
more information regarding risks and uncertainties that could
affect the Company's results of operations or financial condition,
please review the definitive Proxy Statement filed on November 7, 2022, and our Form 10-K filed on
September 28, 2022, with the SEC.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/perspective-therapeutics-and-pharmalogic-announce-collaboration-for-the-development-and-production-of-theranostics-for-cancer-care-301771099.html
SOURCE PharmaLogic Holdings Corp